Elite Pharmaceuticals Inc (ELTP)
0.6168
0.00 (0.00%)
USD |
OTCM |
Nov 22, 16:00
Elite Pharmaceuticals Cash from Financing (Quarterly): -0.3207M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.3207M |
| June 30, 2024 | -0.1749M |
| March 31, 2024 | -0.3614M |
| December 31, 2023 | -0.0307M |
| September 30, 2023 | -0.1795M |
| June 30, 2023 | 3.957M |
| March 31, 2023 | -12.50M |
| December 31, 2022 | -0.0774M |
| September 30, 2022 | 2.385M |
| June 30, 2022 | 11.90M |
| March 31, 2022 | -0.0942M |
| December 31, 2021 | -0.1539M |
| September 30, 2021 | -0.2665M |
| June 30, 2021 | -0.1525M |
| March 31, 2021 | -1.286M |
| December 31, 2020 | -0.1505M |
| September 30, 2020 | -0.245M |
| June 30, 2020 | 0.8114M |
| March 31, 2020 | 0.5008M |
| December 31, 2019 | -0.072M |
| September 30, 2019 | 0.1468M |
| June 30, 2019 | 0.114M |
| March 31, 2019 | 0.3851M |
| December 31, 2018 | 0.2643M |
| September 30, 2018 | 0.5633M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.3542M |
| March 31, 2018 | 0.8475M |
| December 31, 2017 | 0.0813M |
| September 30, 2017 | 0.3368M |
| June 30, 2017 | 0.4054M |
| March 31, 2017 | 1.680M |
| December 31, 2016 | 1.723M |
| September 30, 2016 | 2.317M |
| June 30, 2016 | 2.351M |
| March 31, 2016 | 3.373M |
| December 31, 2015 | 0.8105M |
| September 30, 2015 | 1.600M |
| June 30, 2015 | 2.978M |
| March 31, 2015 | 3.646M |
| December 31, 2014 | 3.637M |
| September 30, 2014 | 4.260M |
| June 30, 2014 | 1.204M |
| March 31, 2014 | 7.401M |
| December 31, 2013 | 2.088M |
| September 30, 2013 | 1.506M |
| June 30, 2013 | 0.352M |
| March 31, 2013 | 0.4758M |
| December 31, 2012 | 0.2983M |
| September 30, 2012 | 0.6358M |
| June 30, 2012 | 0.176M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-12.50M
Minimum
Mar 2023
11.90M
Maximum
Jun 2022
0.1742M
Average
-0.1515M
Median
Cash from Financing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -499.12M |
| BioCardia Inc | 6.122M |
| Zevra Therapeutics Inc | 64.76M |
| Verrica Pharmaceuticals Inc | -0.397M |
| Terns Pharmaceuticals Inc | 163.29M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.457M |
| Cash from Investing (Quarterly) | 0.0176M |
| Free Cash Flow | 1.685M |
| Free Cash Flow Per Share (Quarterly) | 0.0013 |
| Free Cash Flow to Equity (Quarterly) | 1.595M |
| Free Cash Flow to Firm (Quarterly) | 1.653M |
| Free Cash Flow Yield | 0.26% |